Kalmar Investments’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q1
$11.6M Sell
330,742
-296,664
-47% -$9.39M 2.63% 3
2016
Q4
$19.3M Sell
627,406
-34,201
-5% -$1.06M 0.99% 44
2016
Q3
$20M Buy
661,607
+248,929
+60% +$7.51M 0.91% 46
2016
Q2
$11.3M Buy
412,678
+42,035
+11% +$1.07M 0.5% 81
2016
Q1
$9.94M Buy
370,643
+13,295
+4% +$325K 0.41% 86
2015
Q4
$10.1M Buy
357,348
+81,569
+30% +$2.35M 0.25% 119
2015
Q3
$7.68M Sell
275,779
-83,754
-23% -$3.03M 0.18% 134
2015
Q2
$14.8M Sell
359,533
-25,615
-7% -$938K 0.28% 110
2015
Q1
$11.7M Sell
385,148
-9,683
-2% -$251K 0.22% 129
2014
Q4
$7.82M Sell
394,831
-16,210
-4% -$362K 0.15% 146
2014
Q3
$8.18M Sell
411,041
-16,675
-4% -$351K 0.16% 141
2014
Q2
$9.75M Sell
427,716
-135,970
-24% -$2.42M 0.17% 138
2014
Q1
$7.25M Sell
563,686
-331,999
-37% -$4.76M 0.12% 151
2013
Q4
$12.2M Sell
895,685
-29,320
-3% -$350K 0.2% 130
2013
Q3
$10.3M Buy
+925,005
New +$9.2M 0.18% 136

Other funds holding RGEN

Kalmar Investments's RGEN Position: Q1 2017 in Review

Kalmar Investments reduced its Repligen (RGEN) stake by 47% in Q1 2017, selling an estimated $9.39M and leaving 330,742 shares worth $11.6M. The position accounts for 2.63% of the portfolio, ranked #3.

Kalmar Investments first reported a position in RGEN in Q3 2013 and has held it in 15 quarters since. The position peaked at $20M in Q3 2016. 180 funds tracked by Wall St. Rank hold RGEN as of Q1 2017.

  • Kalmar Investments held 330,742 shares of Repligen worth $11.6M as of Q1 2017.
  • Kalmar Investments sold 296,664 Repligen shares in Q1 2017, an estimated $9.39M.
  • Repligen made up 2.63% of Kalmar Investments's portfolio in Q1 2017, its #3 holding.
  • Kalmar Investments first reported a position in Repligen in Q3 2013 and has held it in 15 quarters since.
  • Kalmar Investments's Repligen position peaked at $20M in Q3 2016.
  • 180 funds tracked by Wall St. Rank held Repligen as of Q1 2017.

Based on Kalmar Investments's 13F filing for Q1 2017, filed 26 Apr 2017.